Alectinib energetic against leptomeningeal metastases in ALK-positive NSCLC By Shreeya Nanda.

All patients responded to alectinib treatment, with improvements in symptoms such as headaches, diplopia, fatigue and right-sided weakness. Three individuals demonstrated significant radiographical improvement of leptomeningeal disease also, while the remaining patient had stable central anxious system disease. The treatment appeared to be generally well tolerated, say the researchers, without significant toxicity in three participants. All rights reserved. Neither of the parties endorse or recommend any commercial products, services, or equipment.. Alectinib energetic against leptomeningeal metastases in ALK-positive NSCLC By Shreeya Nanda, Senior medwireNews Reporter Patients with anaplastic lymphoma kinase -rearranged non-small-cell lung cancers who’ve leptomeningeal metastases may reap the benefits of treatment with the second-generation ALK inhibitor alectinib, a case series suggests.Related StoriesTumour DNA in the bloodstream can accurately monitor tumor in real timeNew analysis examines previously unknown top secret to DNA repairDNA tests for Down's syndrome may potentially save lives of unborn babiesOne way to impact that surrounding environment is to attach double-stranded DNA molecules to the surface of a gold nanoparticle. Using surface area plasmon resonance spectroscopy, the investigators could actually measure the subtle adjustments that take place in light emissions as the distance of an attached little bit of DNA transformed in response to interactions with proteins, including DNA-degrading enzymes known as nucleases.